




# Panther Fusion<sup>®</sup> Respiratory Assays

A fully-automated, modular approach to syndromic respiratory testing.<sup>1</sup>

**Syndromic respiratory testing.** Patient-specific results.

On-demand testing with the Panther Fusion<sup>®</sup> assay menu addresses the clinical need to differentiate the overlapping symptoms of respiratory pathogens and SARS-CoV-2 during the winter respiratory season and beyond.



PANTHER  
**FUSION<sup>®</sup> SARS-CoV-2/Flu A/B/RSV**  
Assay

PANTHER  
**FUSION<sup>®</sup> Flu A/B/RSV**  
Assay

PANTHER  
**FUSION<sup>®</sup> AdV/hMPV/RV**  
Assay

PANTHER  
**FUSION<sup>®</sup> Paraflu**  
Assay

PANTHER  
**FUSION<sup>®</sup> Bordetella**  
Assay

Run single or multiple assays from a single patient specimen to detect the most common respiratory pathogens.

## The Panther Fusion Respiratory assays

Right patient. Right test. Right time.



Process 335 Panther Fusion tests or combine Panther Fusion and Aptima<sup>®</sup> assays for up to 500 tests in 8 hours<sup>1</sup>



Provide comprehensive reactivity and specificity results



Choose from the most common respiratory pathogens



Personalise patient testing from a single sample



Control costs by running only the assays needed



Attain 60-day onboard stability with unit dose, ready-to-use reagents



Deliver comprehensive coverage of target analytes



Minimise user interaction and return visits to the system with bulk onboard reagents

**Be prepared for the winter respiratory season with Panther Fusion® assays:**  
a fully-automated, modular approach to syndromic respiratory testing.

**Increase efficiency. Reduce costs.**

Accurate and timely diagnosis of the cause of respiratory tract infections has a number of benefits for patients and their communities, including:

- Helps reduce the potential for further development of antimicrobial resistance due to antibiotics.<sup>2</sup>
- Provides valued information to public health authorities regarding which viruses are circulating in the community.<sup>5</sup>
- Improves patient care and helps decrease costs.<sup>3,4</sup>
- Assists infection control personnel to provide appropriate measures to minimise nosocomial spread.<sup>6</sup>

**Proven performance and comprehensive design you can trust.**

PANTHER  
**FUSION® SARS-CoV-2/Flu A/B/RSV**  
Assay

PANTHER  
**FUSION® Flu A/B/RSV**  
Assay

PANTHER  
**FUSION® AdV/hMPV/RV**  
Assay

PANTHER  
**FUSION® Parainfluenza**  
Assay

PANTHER  
**FUSION® Bordetella**  
Assay

	High Sensitivity and Specificity <sup>7</sup>	
	Sensitivity	Specificity
SARS-CoV-2	98.1%	98.5%
Influenza A	100%	99.6%
Influenza B	98.1%	99.6%
RSV	98.1%	100%
Influenza A	98.8%	99.0%
Influenza B	100%	99.8%
RSV	99.3%	99.0%
Adenovirus	98.3%	97.0%
hMPV	100%	94.6%
RV	90.1%	95.4%
Parainfluenza 1	100%	100%
Parainfluenza 2	100%	100%
Parainfluenza 3	100%	99.6%
Parainfluenza 4	98.1%	100%
Bordetella pertussis	100%	96.8%
Bordetella parapertussis	100%	99.6%

**Verified sample collection**

- ✓ BD Universal Viral Transport System
- ✓ COPAN Universal Transport Medium
- ✓ Remel MicroTest M4, M4RT, M5 or M6 formulations\*

**RUN ON  
PANTHER  
FUSION®**



CE 2797 **EC REP** Hologic BV, Da Vincilaan 5, 1930 Zaventem, Belgium. NB Number wherever applicable. EC Rep details wherever applicable.

**Diagnostic Solutions | Hologic.com | euinfo@hologic.com**

\*Panther Fusion SARS-CoV-2/Flu A/B/RSV assay and Flu A/B/RSV assay validated only for nasopharyngeal swab in viral transport medium and universal transport medium.

**References:** 1. Panther / Panther Fusion Operators Manual AW-26055-001 Rev. 001, San Diego, CA Hologic, Inc., 2022. 2. Pinsky BA, Hayden RT. Cost-Effective Respiratory Virus Testing. J Clin Microbiol. 2019 Aug 26;57(9):e00373-19. doi: 10.1128/JCM.00373-19. PMID: 31142607; PMCID: PMC6711893. [page 7] 3. https://www.health.vic.gov.au/health-advisories/testing-for-respiratory-pathogens Accessed August, 2022. 4. Pinsky BA, Hayden RT. Cost-Effective Respiratory Virus Testing. J Clin Microbiol. 2019 Aug 26;57(9):e00373-19. doi: 10.1128/JCM.00373-19. PMID: 31142607; PMCID: PMC6711893. [page 1] 5. WHO-2019-nCoV-Surveillance-Guidance-20221-eng.pdf [page 7] https://apps.who.int/iris/handle/10665/351761 Accessed August, 2022. 6. Lim RHF, Htun HL, Li AL, Guo H, Kyaw WM, Hein AA, Ang B, Chow A. Fending off Delta - Hospital measures to reduce nosocomial transmission of COVID-19. Int J Infect Dis. 2022 Apr;117:139-145. doi: 10.1016/j.ijid.2022.01.069. Epub 2022 Feb 4. PMID: 35124240; PMCID: PMC8813202. 7. Panther Fusion SARS-CoV-2/Flu A/B/RSV assay [package insert]. AW-25328-001. Rev 001. San Diego, CA: Hologic, Inc.; 2022. Panther Fusion Flu A/B/RSV assay [package insert]. AW-23081-001. Rev 001. San Diego, CA: Hologic, Inc.; 2022. Panther Fusion AdV/hMPV/RV assay [package insert]. AW-23710-001. Rev 001. San Diego, CA: Hologic, Inc.; 2022. Panther Fusion Parainfluenza assay [package insert]. AW-23708-001. Rev 001. San Diego, CA: Hologic, Inc.; 2022. Panther Fusion Bordetella assay [package insert]. AW-18637. Rev 001. San Diego, CA: Hologic, Inc.; 2018.

SS-00682-EUR-EN Rev 004 © 2023 Hologic, Inc. All rights reserved. Hologic, Aptima, Panther Fusion and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries. All other trademarks, registered trademarks, and product names are the property of their respective owners. This information is intended for medical professionals and is not intended as a product solicitation or promotion where such activities are prohibited. Because Hologic materials are distributed through websites, eBroadcasts and tradeshows, it is not always possible to control where such materials appear. For specific information on what products are available for sale in a particular country, please contact your local Hologic representative or write to euinfo@hologic.com.